Under the terms of the agreement, Aptamer Group will develop validated Optimer ligands against critical targets for ProAxsis’s diagnostic assays. ProAxsis will then assess Optimer performance within their current diagnostics assays, with the view to potentially replacing the antibodies in their commercial diagnostic assays. Aptamer Group will receive initial upfront payments with the potential for long-term royalty fees upon project success and the integration of the Optimer reagents into ProAxsis’s diagnostic assays.
Optimer ligands are nucleic acid-based affinity ligands that deliver high temperature stability which can remove the requirement for cold-chain supply to enable simple, cost-effective and more sustainable global logistics. As Optimers are manufactured without reliance on biological systems, they are highly batch consistent and offer increased security of supply compared to protein-based affinity ligands.
For the full story, please visit the Aptamer Group website.